Annual FCF
-$16.19 M
-$1.06 M-6.99%
December 31, 2023
Summary
- As of February 8, 2025, CYTH annual free cash flow is -$16.19 million, with the most recent change of -$1.06 million (-6.99%) on December 31, 2023.
- During the last 3 years, CYTH annual FCF has fallen by -$7.59 million (-88.37%).
- CYTH annual FCF is now -4150.90% below its all-time high of $399.60 thousand, reached on December 31, 2013.
Performance
CYTH Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$8.19 M
-$4.34 M-112.89%
September 30, 2024
Summary
- As of February 8, 2025, CYTH quarterly free cash flow is -$8.19 million, with the most recent change of -$4.34 million (-112.89%) on September 30, 2024.
- Over the past year, CYTH quarterly FCF has dropped by -$3.90 million (-90.75%).
- CYTH quarterly FCF is now -1790.20% below its all-time high of $484.70 thousand, reached on June 30, 2013.
Performance
CYTH Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$22.52 M
-$4.15 M-22.60%
September 30, 2024
Summary
- As of February 8, 2025, CYTH TTM free cash flow is -$22.52 million, with the most recent change of -$4.15 million (-22.60%) on September 30, 2024.
- Over the past year, CYTH TTM FCF has dropped by -$6.33 million (-39.13%).
- CYTH TTM FCF is now -4330.23% below its all-time high of $532.30 thousand, reached on September 30, 2013.
Performance
CYTH TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
CYTH Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.0% | -90.8% | -39.1% |
| 3 y3 years | -88.4% | -90.8% | -39.1% |
| 5 y5 years | -407.2% | -90.8% | -39.1% |
CYTH Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -7.7% | at low | -213.7% | at low | -63.3% | at low |
| 5 y | 5-year | -145.6% | at low | -409.4% | at low | -241.7% | at low |
| alltime | all time | -4150.9% | at low | -1790.2% | at low | -4330.2% | at low |
Cyclo Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.19 M(+112.9%) | -$22.52 M(+22.6%) |
| Jun 2024 | - | -$3.85 M(-37.8%) | -$18.37 M(+2.1%) |
| Mar 2024 | - | -$6.18 M(+43.9%) | -$18.00 M(+11.2%) |
| Dec 2023 | -$16.19 M(+7.0%) | -$4.29 M(+6.3%) | -$16.18 M(+10.6%) |
| Sep 2023 | - | -$4.04 M(+16.2%) | -$14.64 M(+6.2%) |
| Jun 2023 | - | -$3.48 M(-20.4%) | -$13.79 M(-6.0%) |
| Mar 2023 | - | -$4.37 M(+59.1%) | -$14.66 M(-3.1%) |
| Dec 2022 | -$15.13 M(+0.7%) | -$2.75 M(-13.9%) | -$15.13 M(+0.9%) |
| Sep 2022 | - | -$3.19 M(-26.7%) | -$14.99 M(+1.1%) |
| Jun 2022 | - | -$4.36 M(-9.9%) | -$14.83 M(-0.7%) |
| Mar 2022 | - | -$4.83 M(+85.1%) | -$14.94 M(-0.6%) |
| Dec 2021 | -$15.03 M(+74.9%) | -$2.61 M(-13.7%) | -$15.03 M(-2.9%) |
| Sep 2021 | - | -$3.03 M(-32.2%) | -$15.48 M(+10.1%) |
| Jun 2021 | - | -$4.46 M(-9.4%) | -$14.06 M(+20.6%) |
| Mar 2021 | - | -$4.93 M(+60.9%) | -$11.66 M(+35.7%) |
| Dec 2020 | -$8.59 M(+30.4%) | -$3.06 M(+90.3%) | -$8.59 M(+10.9%) |
| Sep 2020 | - | -$1.61 M(-22.1%) | -$7.75 M(-0.2%) |
| Jun 2020 | - | -$2.06 M(+11.0%) | -$7.77 M(+7.5%) |
| Mar 2020 | - | -$1.86 M(-16.2%) | -$7.22 M(+9.6%) |
| Dec 2019 | -$6.59 M(+106.5%) | -$2.22 M(+36.8%) | -$6.59 M(+21.4%) |
| Sep 2019 | - | -$1.62 M(+6.7%) | -$5.43 M(+28.2%) |
| Jun 2019 | - | -$1.52 M(+24.0%) | -$4.23 M(+15.0%) |
| Mar 2019 | - | -$1.23 M(+16.2%) | -$3.68 M(+15.3%) |
| Dec 2018 | -$3.19 M(+4.0%) | -$1.06 M(+146.9%) | -$3.19 M(+2.3%) |
| Sep 2018 | - | -$427.70 K(-55.8%) | -$3.12 M(-4.7%) |
| Jun 2018 | - | -$968.40 K(+31.0%) | -$3.27 M(+24.9%) |
| Mar 2018 | - | -$739.30 K(-25.0%) | -$2.62 M(-14.6%) |
| Dec 2017 | -$3.07 M(+3.7%) | -$985.40 K(+69.4%) | -$3.07 M(+15.9%) |
| Sep 2017 | - | -$581.60 K(+84.0%) | -$2.65 M(-9.4%) |
| Jun 2017 | - | -$316.10 K(-73.4%) | -$2.92 M(-14.5%) |
| Mar 2017 | - | -$1.19 M(+110.2%) | -$3.42 M(+15.5%) |
| Dec 2016 | -$2.96 M(+22.9%) | -$564.40 K(-34.1%) | -$2.96 M(-10.3%) |
| Sep 2016 | - | -$856.30 K(+5.2%) | -$3.30 M(+9.1%) |
| Jun 2016 | - | -$813.60 K(+12.1%) | -$3.02 M(+15.6%) |
| Mar 2016 | - | -$726.00 K(-19.7%) | -$2.62 M(+8.6%) |
| Dec 2015 | -$2.41 M(+199.2%) | -$904.20 K(+56.0%) | -$2.41 M(+30.0%) |
| Sep 2015 | - | -$579.80 K(+42.9%) | -$1.85 M(+17.4%) |
| Jun 2015 | - | -$405.80 K(-21.8%) | -$1.58 M(+8.2%) |
| Mar 2015 | - | -$518.80 K(+48.7%) | -$1.46 M(+81.2%) |
| Dec 2014 | -$805.00 K(-301.5%) | -$349.00 K(+14.5%) | -$805.10 K(+18.9%) |
| Sep 2014 | - | -$304.90 K(+6.5%) | -$677.10 K(+94.0%) |
| Jun 2014 | - | -$286.40 K(-311.8%) | -$349.10 K(-182.7%) |
| Mar 2014 | - | $135.20 K(-161.2%) | $422.00 K(+5.6%) |
| Dec 2013 | $399.60 K(-471.0%) | -$221.00 K(-1056.7%) | $399.60 K(-24.9%) |
| Sep 2013 | - | $23.10 K(-95.2%) | $532.30 K(+4.1%) |
| Jun 2013 | - | $484.70 K(+329.7%) | $511.10 K(+773.7%) |
| Mar 2013 | - | $112.80 K(-227.7%) | $58.50 K(-154.3%) |
| Dec 2012 | -$107.70 K | -$88.30 K(-4747.4%) | -$107.70 K(-269.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | $1900.00(-94.1%) | $63.70 K(-158.5%) |
| Jun 2012 | - | $32.10 K(-160.1%) | -$108.90 K(-68.1%) |
| Mar 2012 | - | -$53.40 K(-164.3%) | -$341.80 K(-7.1%) |
| Dec 2011 | -$368.00 K(+58.1%) | $83.10 K(-148.7%) | -$367.90 K(+4.1%) |
| Sep 2011 | - | -$170.70 K(-15.0%) | -$353.40 K(+15.8%) |
| Jun 2011 | - | -$200.80 K(+152.6%) | -$305.30 K(+34.8%) |
| Mar 2011 | - | -$79.50 K(-181.5%) | -$226.40 K(-2.8%) |
| Dec 2010 | -$232.80 K(-459.8%) | $97.60 K(-179.6%) | -$232.90 K(-16.6%) |
| Sep 2010 | - | -$122.60 K(+0.6%) | -$279.30 K(+131.4%) |
| Jun 2010 | - | -$121.90 K(+41.7%) | -$120.70 K(+2266.7%) |
| Mar 2010 | - | -$86.00 K(-268.0%) | -$5100.00(-107.9%) |
| Dec 2009 | $64.70 K(-428.4%) | $51.20 K(+42.2%) | $64.70 K(+8.2%) |
| Sep 2009 | - | $36.00 K(-671.4%) | $59.80 K(-2.1%) |
| Jun 2009 | - | -$6300.00(-61.1%) | $61.10 K(-235.2%) |
| Mar 2009 | - | -$16.20 K(-135.0%) | -$45.20 K(+129.4%) |
| Dec 2008 | -$19.70 K(-106.9%) | $46.30 K(+24.1%) | -$19.70 K(-173.8%) |
| Sep 2008 | - | $37.30 K(-133.1%) | $26.70 K(-50.2%) |
| Jun 2008 | - | -$112.60 K(-1310.8%) | $53.60 K(-81.5%) |
| Mar 2008 | - | $9300.00(-90.0%) | $290.10 K(+1.5%) |
| Dec 2007 | $285.90 K(<-9900.0%) | $92.70 K(+44.4%) | $285.90 K(+51.8%) |
| Sep 2007 | - | $64.20 K(-48.2%) | $188.30 K(+4.5%) |
| Jun 2007 | - | $123.90 K(+2329.4%) | $180.20 K(-1255.1%) |
| Mar 2007 | - | $5100.00(-204.1%) | -$15.60 K(+940.0%) |
| Dec 2006 | -$1500.00(-101.4%) | -$4900.00(-108.7%) | -$1500.00(-119.0%) |
| Sep 2006 | - | $56.10 K(-178.0%) | $7900.00(-217.9%) |
| Jun 2006 | - | -$71.90 K(-474.5%) | -$6700.00(-114.2%) |
| Mar 2006 | - | $19.20 K(+326.7%) | $47.30 K(-55.5%) |
| Dec 2005 | $106.20 K(-14.7%) | $4500.00(-89.2%) | $106.20 K(+88.3%) |
| Sep 2005 | - | $41.50 K(-331.8%) | $56.40 K(-46.0%) |
| Jun 2005 | - | -$17.90 K(-122.9%) | $104.50 K(+20.0%) |
| Mar 2005 | - | $78.10 K(-272.4%) | $87.10 K(-30.0%) |
| Dec 2004 | $124.50 K(+1120.6%) | -$45.30 K(-150.6%) | $124.50 K(-17.1%) |
| Sep 2004 | - | $89.60 K(-353.8%) | $150.10 K(+129.2%) |
| Jun 2004 | - | -$35.30 K(-130.6%) | $65.50 K(-46.7%) |
| Mar 2004 | - | $115.50 K(-686.3%) | $122.90 K(+1093.2%) |
| Dec 2003 | $10.20 K(-66.3%) | -$19.70 K(-494.0%) | $10.30 K(-277.6%) |
| Sep 2003 | - | $5000.00(-77.4%) | -$5800.00(-111.5%) |
| Jun 2003 | - | $22.10 K(+662.1%) | $50.40 K(+119.1%) |
| Mar 2003 | - | $2900.00(-108.1%) | $23.00 K(-24.1%) |
| Dec 2002 | $30.30 K(-192.7%) | -$35.80 K(-158.5%) | $30.30 K(-54.2%) |
| Sep 2002 | - | $61.20 K(-1254.7%) | $66.20 K(+48.1%) |
| Jun 2002 | - | -$5300.00(-152.0%) | $44.70 K(-2729.4%) |
| Mar 2002 | - | $10.20 K(>+9900.0%) | -$1700.00(-94.8%) |
| Dec 2001 | -$32.70 K(-74.0%) | $100.00(-99.7%) | -$32.70 K(-0.3%) |
| Sep 2001 | - | $39.70 K(-176.8%) | -$32.80 K(-54.8%) |
| Jun 2001 | - | -$51.70 K(+148.6%) | -$72.50 K(+248.6%) |
| Mar 2001 | - | -$20.80 K | -$20.80 K |
| Dec 2000 | -$125.70 K | - | - |
FAQ
- What is Cyclo Therapeutics annual free cash flow?
- What is the all time high annual FCF for Cyclo Therapeutics?
- What is Cyclo Therapeutics annual FCF year-on-year change?
- What is Cyclo Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Cyclo Therapeutics?
- What is Cyclo Therapeutics quarterly FCF year-on-year change?
- What is Cyclo Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Cyclo Therapeutics?
- What is Cyclo Therapeutics TTM FCF year-on-year change?
What is Cyclo Therapeutics annual free cash flow?
The current annual FCF of CYTH is -$16.19 M
What is the all time high annual FCF for Cyclo Therapeutics?
Cyclo Therapeutics all-time high annual free cash flow is $399.60 K
What is Cyclo Therapeutics annual FCF year-on-year change?
Over the past year, CYTH annual free cash flow has changed by -$1.06 M (-6.99%)
What is Cyclo Therapeutics quarterly free cash flow?
The current quarterly FCF of CYTH is -$8.19 M
What is the all time high quarterly FCF for Cyclo Therapeutics?
Cyclo Therapeutics all-time high quarterly free cash flow is $484.70 K
What is Cyclo Therapeutics quarterly FCF year-on-year change?
Over the past year, CYTH quarterly free cash flow has changed by -$3.90 M (-90.75%)
What is Cyclo Therapeutics TTM free cash flow?
The current TTM FCF of CYTH is -$22.52 M
What is the all time high TTM FCF for Cyclo Therapeutics?
Cyclo Therapeutics all-time high TTM free cash flow is $532.30 K
What is Cyclo Therapeutics TTM FCF year-on-year change?
Over the past year, CYTH TTM free cash flow has changed by -$6.33 M (-39.13%)